B. L. D. Shetty

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

H. Gendelman, J. McMillan, Samuel M. Cohen, 2021, Nature Communications.

A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug

J. Meza, H. Gendelman, J. McMillan, 2020, Nature Materials.

Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir

H. Gendelman, J. McMillan, N. Gautam, 2021, Nature Communications.

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

H. Gendelman, J. McMillan, H. Fox, 2017, Biomaterials.

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

G. Siuzdak, T. Wilson, J. Meza, 2017, npj Parkinson's Disease.

Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L‐Dopa‐induced dyskinesia in parkinsonian rats

C. Fletcher, S. Papa, R. Amara, 2020, Genes, brain, and behavior.

Pathways for Dolutegravir Transformation from a Daily Oral to a Once-a-Year Parenteral Medicine

H. Gendelman, J. McMillan, A. Dahan, 2022 .